| Ian Daniel Barlow, OTR/L | |
|
140 Point Judith Rd, Unit A13, Narragansett, RI 02882-3451 | |
| (401) 792-0900 | |
| (401) 782-2916 |
| Full Name | Ian Daniel Barlow |
|---|---|
| Gender | Male |
| Speciality | Occupational Therapist |
| Location | 140 Point Judith Rd, Narragansett, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154366342 | NPI | - | NPPES |
| 25592-1 | Other | RI | BLUE CROSS |
| 31453-8 | Other | RI | BLUE CROSS |
| 410678 | Other | RI | BLUE CHIP |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OT 00949 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ian Daniel Barlow, OTR/L 21 Johnson Pl, Wakefield, RI 02879-4001 Ph: (401) 862-4620 | Ian Daniel Barlow, OTR/L 140 Point Judith Rd, Unit A13, Narragansett, RI 02882-3451 Ph: (401) 792-0900 |
News Archive
Italian and German scientists have designed peptides to target the protein-protein interface of a key enzyme in DNA synthesis crucial for cancer growth. The peptides act by a novel inhibitory mechanism and curb cancer cell growth in drug resistant ovarian cancer cells.
Positive results from additional analyses of PRIDE-HD and Open-HART trials with pridopidine published in a peer-reviewed journal, The Journal of Huntington's Disease.
"The health ministry has formed a committee to frame a policy for antibiotic use, following an uproar over a Lancet study that traced a drug-resistant bacterial superbug's origins to India," LiveMint.com reports. The panel will also look into the "excessive use of antibiotics among Indians," partly fueled by self-medication, that has increased resistance to the drugs. The article notes that the Indian government "rejected the findings of the report" but has "taken note of a lack of policy on antibiotics" (Pandeya, 9/3).
Congressional Republicans continue to appear divided over what their strategy should be if the Supreme Court strikes down all or part of the health law. More immediately, though, Sen. Orrin Hatch, R-Utah, is targeting the measure's device tax as part of the Senate's consideration of a bill that would reauthorize the Food and Drug Administration user fees.
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy.
› Verified 4 days ago
Linda S. Curry, P.T. Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 14 Woodruff Ave, Suite 7, Narragansett, RI 02882 Phone: 401-782-0500 Fax: 401-788-2253 | |
Sheila R Sweeney, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 14 Woodruff Ave, Suite 7, Narragansett, RI 02882 Phone: 401-788-2050 Fax: 401-788-2253 | |
Barlow Rehabilitation, Inc Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 140 Point Judith Rd, Unit C6, Narragansett, RI 02882 Phone: 401-792-0900 Fax: 401-782-2916 | |
Mrs. Kathleen Corbett Schlenz, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5 Woodruff Ave, Narragansett, RI 02882 Phone: 401-284-1000 |